5 new drugs and exclusive rights sale + royaltiesANVISA x 2, 505(b)2, NDA, generic Epidiolex, Medipharm is under no obligation to supply their FDA approved API for generic Epidiolex to any pharma company that approaches and can sell the rights to their API on an exclusive basis including a royalty agreement. The same holds true for ANVISA x 2 drugs, 505(b)2 and the NDA.
Strachan mentioned Epidiolex global sales are approximately $ 1 billion USD.
Will Elmer Fudd sell the rights of their exclusive formulation API for generic Epidiolex to Apotex as an exclusive deal? They can then produce that exclusive formulation API with a royalty agreement on an exclusive basis to their partner where the big lights are, Toronto.
That deal alone is a new 52 week high for Medipharm and any decent CEO can do that but Elmer Fudd as CEO of LABS needs to get booted out.